Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and Marrow Transplant Research
Open Access
- 1 February 2013
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 19 (2) , 173-179
Abstract
No abstract availableKeywords
Funding Information
- Health Service Grant/Cooperative Agreement (U24-CA76518)
- National Cancer Institute (NCI)
- National Heart, Lung and Blood Institute (NHLBI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- NHLBI and NCI (5U01HL069294)
- Health Resources and Services Administration (HRSA/DHHS) (N00014-06-1-0704)
- Office of Naval Research (N00014-08-1-0058)
- Allos, Inc.
- Amgen, Inc.
- Angioblast
- Anonymous donation to the Medical College of Wisconsin
- Ariad; Be the Match Foundation
- Blue Cross and Blue Shield Association
- Buchanan Family Foundation
- CaridianBCT
- Celgene Corporation
- CellGenix, GmbH
- Children's Leukemia Research Association
- Fresenius-Biotech North America, Inc.
- Gamida Cell Teva Joint Venture Ltd.
- Genentech, Inc.
- Genzyme Corporation
- GlaxoSmithKline
- HistoGenetics, Inc.
- Kiadis Pharma
- Leukemia & Lymphoma Society
- Medical College of Wisconsin
- Merck & Co, Inc.
- Millennium: The Takeda Oncology Co.
- Milliman USA, Inc.
- Miltenyi Biotec, Inc.
- National Marrow Donor Program
- Optum Healthcare Solutions, Inc.
- Osiris Therapeutics, Inc.
- Otsuka America Pharmaceutical, Inc.
- RemedyMD
- Sanofi
- Seattle Genetics
- Sigma-Tau Pharmaceuticals
- Soligenix, Inc.
- StemCyte, A Global Cord Blood Therapeutics Co.
- Stemsoft Software, Inc.
- Swedish Orphan Biovitrum
- Tarix Pharmaceuticals
- Teva Neuroscience, Inc.
- THERAKOS, Inc.
- Wellpoint, Inc
This publication has 13 references indexed in Scilit:
- Burkitt lymphoma in adultsBritish Journal of Haematology, 2011
- Outcomes of Patients With Burkitt Lymphoma Older Than Age 40 Treated With Intensive Chemotherapeutic RegimensClinical Lymphoma Myeloma and Leukemia, 2009
- A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)Blood, 2008
- Biology and treatment of Burkittʼs lymphomaCurrent Opinion in Hematology, 2007
- Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemiaCancer, 2006
- Adult Burkitt leukemia and lymphomaBlood, 2004
- Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphomaCancer, 2004
- The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemiaBlood, 2001
- Treatment of Patients with High Grade Non-Hodgkin's Lymphomas and Central Nervous System Involvement: Is Radiation an Essential Component of Therapy?Leukemia & Lymphoma, 1996
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958